Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): updated results from a Phase I/II Study
Budde, E. L. Bartlett, N. L. Giri, P. Schuster, S. J. Assouline, S. Yoon, S. S. Fay, K. Matasar, M. J. Gutierrez, N. C. Marlton, P.
Budde, E. L.
Bartlett, N. L.
Giri, P.
Schuster, S. J.
Assouline, S.
Yoon, S. S.
Fay, K.
Matasar, M. J.
Gutierrez, N. C.
Marlton, P.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Budde EL, Bartlett NL, Giri P, Schuster SJ, Assouline S, Yoon SS, et al. Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study. Blood. 2022 Nov;140:3753-5. PubMed PMID: WOS:000893223203346.